Literature DB >> 16651205

Improvement in sexual functioning and satisfaction in nonresponders to testosterone gel: clinical effectiveness in hypogonadal, HIV-positive males.

Shannon Schrader1, Anthony Mills, Mark Scheperle, Jon E Block.   

Abstract

Impairment in gonadal function with reduced testosterone (T) levels is commonly associated with HIV infection and patients often complain of diminished libido and sexual dysfunction. The effectiveness of Testim 1% (Auxilium Pharmaceuticals, Inc., Norristown, Pennsylvania) topical T gel was evaluated in HIV-positive males who failed to experience satisfactory symptom relief following prior treatment with AndroGel 1% (Solvay Pharmaceuticals, Inc., Marietta, Georgia). In this open-label study, consecutive subjects were randomly assigned to experimental treatment with Testim 1% (5 g) or to maintenance therapy (control group) with AndroGel 1% (5 g). Twenty-four experimental subjects and 24 control subjects were followed for 4 weeks to evaluate improvements in sexual functioning and satisfaction. Changes from baseline in the 5 domains of the Brief Male Sexual Function Inventory (BMSFI) were compared between groups. The average percentage improvement favored the experimental treatment in all 5 comparisons of the BMSFI, including sexual drive (53% vs 18%, P < 0.001), erectile function (49% vs 7%, P < 0.004), ejaculatory function (15% vs 8%, P < 0.14), problem assessment (59% vs 12%, P < 0.003), and sexual satisfaction (58% vs 9%, P < 0.006). A greater percentage of subjects also reported satisfaction with the experimental treatment (85% vs 48%, P < 0.03), and these subjects were less likely to require upward dose titration at the final follow-up visit (30% vs 74%, P = 0.01). It is hypothesized that the results of the current study may be explained, in part, by an improved pharmacokinetic profile of the experimental intervention. Consideration of Testim 1% gel in HIV patients who have an inadequate response to prior T therapy is encouraged, although it is difficult to estimate the contribution of nonspecific study effects (eg, placebo) in this trial.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16651205     DOI: 10.1016/s1098-3597(05)80095-x

Source DB:  PubMed          Journal:  Clin Cornerstone        ISSN: 1873-4480


  3 in total

1.  Sexual Dysfunctions of HIV-Positive Men: Associated Factors, Pathophysiology Issues, and Clinical Management.

Authors:  Marco de Tubino Scanavino
Journal:  Adv Urol       Date:  2011-10-20

Review 2.  Safety and efficacy of testosterone gel in the treatment of male hypogonadism.

Authors:  Kishore M Lakshman; Shehzad Basaria
Journal:  Clin Interv Aging       Date:  2009-11-18       Impact factor: 4.458

3.  Sexual Dysfunction, Depression and Quality of Life in Patients With HIV Infection.

Authors:  Mahmood Amini Lari; Hosain Faramarzi; Mesbah Shams; Maryam Marzban; Hasan Joulaei
Journal:  Iran J Psychiatry Behav Sci       Date:  2013
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.